Expression of the fibroblast growth factor-2 isoforms and the FGF receptor 1–4 transcripts in the rat model system of Parkinson's disease

2004 ◽  
Vol 360 (3) ◽  
pp. 117-120 ◽  
Author(s):  
Peter Claus ◽  
Stefan Werner ◽  
Marco Timmer ◽  
Claudia Grothe
1995 ◽  
Vol 1 (1) ◽  
pp. 53-58 ◽  
Author(s):  
Hldeichi Takayama ◽  
Jasodhara Ray ◽  
Heather K. Raymon ◽  
Andrew Baird ◽  
Joanna Hogg ◽  
...  

1999 ◽  
Vol 77 (6) ◽  
pp. 569-575 ◽  
Author(s):  
Paramjit S Tappia ◽  
Raymond R Padua ◽  
Vincenzo Panagia ◽  
Elissavet Kardami

Although fibroblast growth factor-2 (FGF-2) plays an important role in cardioprotection and growth, little is known about the signals triggered by it in the adult heart. We therefore examined FGF-2-induced effects on phosphoinositide-specific phospholipase C (PI-PLC) isozymes, which produce second messengers linked to the inotropic and hypertrophic response of the myocardium. FGF-2, administered by retrograde perfusion to the isolated heart, induced an increase in inositol-1,4,5-trisphosphate levels in the cytosol, as well as an increase in total PI-PLC activity associated with sarcolemmal and cytosolic fractions. Furthermore FGF-2 induced a time-dependent elevation in cardiomyocyte membrane-associated PLC gamma1 and PLC β1 activities, assayed in immunoprecipitated fractions, and moreover, increased the membrane levels of PLC β1 and PLC β3. Activation of PLC β is suggestive of FGF-2-induced cross-talk between FGF-receptor tyrosine kinase and G-protein-coupled signaling in adult cardiomyocytes and underscores the importance of FGF-2 in cardiac physiology.Key words: FGF-2, signal transduction, PLC gamma, PLC β, cardiomyocytes.


2005 ◽  
Vol 27 (3) ◽  
pp. 315-324 ◽  
Author(s):  
Francesca Madiai ◽  
Virginia M. Goettl ◽  
Syed-Rehan Hussain ◽  
Alec R. Clairmont ◽  
Robert L. Stephens ◽  
...  

1999 ◽  
Vol 56 (3) ◽  
pp. 883-897 ◽  
Author(s):  
Jürgen Floege ◽  
Kelly L. Hudkins ◽  
Frank Eitner ◽  
Yan Cui ◽  
Richard S. Morrison ◽  
...  

2020 ◽  
Author(s):  
Miaomiao Li ◽  
Junqing Yang ◽  
Oumei Cheng ◽  
Zhe Peng ◽  
Yin Luo ◽  
...  

Abstract Background: Stem cells from different sources could differentiate into dopamine-producing cells and ameliorate behavioral deficits in Parkinsonian models. Especially, human bone marrow mesenchymal stem cells (hBMSCs) have many advantages without ethical dispute. Liver X receptor s (LXRs) are involved in the maintenance of the normal function of the central nervous system myelin. We have reported the induction of cocktail-induced da phenotypes from adult rat BMSCs by using sonic hedgehog (SHH), fibroblast growth factor 8 (FGF8), basic fibroblast growth factor (bFGF) and TO901317 (agonist of LXRs) with 87.42% of efficiency in 6 days of period of induction. But the previous work did not verify whether the induced cells had the corresponding neural function. Methods: In this study, we demonstrated that TO901317 could promote the differentiation of hBMSCs into dopaminergic neurons. Neuronal markers (Tuj1, Neun and Nestin), dopamine neuron markers (tyrosine hydroxylase, TH), LXRa and LXRb were detected by immunofluorescence. RT-qPCR was used to measure the mRNA expressions of adenosine triphosphate-binding cassette transporter A1 (ABCA1). Western Blotting detected the changes of LXRa, LXRb and TH expression. Results: TO901317 significantly enhanced the differentiation from hBMSCs to DA neurons. Only the LXR+GF group released dopamine by the result of enzyme linked immunosorbent assay (ELISA). Compared with the control group and GF group, the optimal time for differentiation of hBMSCs treated by 0.5mM TO901317 combined with GF was six days. And the maximum induction efficiency was 91.67%. After transplanting induced-cells into Parkinson's disease rats, the symptoms of Parkinson's rats decreased, and the number of dopamine neurons increased in the substantia nigra and striatum. Conclusions: TO901317 promoted differentiation of hBMSCs into dopamine neurons may be related to activation of LXR-ABCA1 signaling pathway. These data suggest that TO901317 may serve as a potential therapeutic methods for Parkinson's disease.


Sign in / Sign up

Export Citation Format

Share Document